| Assessment Status | NCPE assessment complete |
| HTA ID | - |
| Drug | Patiromer |
| Brand | Veltassa® |
| Indication | For the treatment of hyperkalaemia in adults. |
| Assessment Process | |
| Rapid review commissioned | 11/10/2017 |
| Rapid review completed | 17/11/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 20/11/2017 |
| Pre-submission consultation with Applicant | 16/01/2018 |
| Full submission received from Applicant | 13/04/2018 |
| Preliminary review sent to Applicant | 15/10/2018 |
| NCPE assessment re-commenced | 13/11/2018 |
| Factual accuracy sent to Applicant | 21/01/2019 |
| NCPE assessment re-commenced | 04/02/2019 |
| NCPE assessment completed | 13/02/2019 |
| NCPE assessment outcome | The NCPE recommends that patiromer (Veltassa®) not be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Re-submission of HTA
| NCPE Assessment Process | Assessment process complete |
| Re-submission of HTA commissioned by the HSE | 30/06/2020 |
| Pre-submission consultation with Applicant | 23/11/2020 |
| Full submission received from Applicant | May 2021 |
| The NCPE recommends that patiromer (Veltassa®) not be considered for reimbursement, on the basis of the submitted evidence*. | |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.